Contineum Therapeutics, Inc.

Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.

CTNM | US

Overview

Corporate Details

ISIN(s):: US21217B1008
LEI:
Country:: United States of America
Address:: 3565 GENERAL ATOMICS COURT, SUITE 200, 92121 SAN DIEGO
Website:: https://www.contineum-tx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops novel, oral small molecule therapies. The company focuses on pioneering treatments for conditions at the intersection of neuroscience, inflammation, and immunology (NI&I). Its pipeline is based on clinically validated biological targets and includes a potential best-in-class LPA1R antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS), and a potential first-in-class M1R antagonist for major depressive disorder (MDD) in collaboration with a Johnson & Johnson company. Formerly Pipeline Therapeutics, Contineum aims to develop impactful treatments for serious neurological, inflammatory, and fibrotic diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Contineum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Contineum Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Contineum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
OPTUS Pharmaceutical Co., Ltd. Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.	South Korea	131030
Opus Genetics, Inc. Developing gene therapies for inherited retinal diseases and other blinding conditions.	United States of America	IRD
ORAGENICS INC Biotech developing intranasal drugs for concussion and other brain disorders.	United States of America	OGEN
Oramed Pharmaceuticals Inc. Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.	Israel	ORMP
ORASURE TECHNOLOGIES INC Develops and distributes point-of-care diagnostic tests and sample collection devices.	United States of America	OSUR
Orexo Develops pharmaceuticals & digital health for opioid use disorder in the US market.	Sweden	ORX
ORGANIGRAM GLOBAL INC. Licensed producer of indoor-grown cannabis and derived products for medical & recreational consumers.	United States of America	OGI
Organon & Co. A global healthcare company focused on women's health, biosimilars, and established brands worldwide.	United States of America	OGN
Oric Pharmaceuticals, Inc. Developing therapies to overcome resistance in lung and prostate cancer.	United States of America	ORIC
Orion Oyj Develops and manufactures human/vet pharma, APIs, and generics for global markets.	Finland	ORNAV